|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 89 No. 12 (June 15), 1997:
pp. 4531-4536
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
By
Sergio Giralt,
Elihu Estey,
Maher Albitar,
Koen van Besien,
Gabriela Rondón,
Paolo Anderlini,
Susan O'Brien,
Issa Khouri,
James Gajewski,
Rakesh Mehra,
David Claxton,
Borje Andersson,
Miloslav Beran,
Donna Przepiorka,
Charles Koller,
Steve Kornblau,
Martin Körbling,
Michael Keating,
Hagop Kantarjian, and
Richard Champlin
From the Department of Hematology and the Department of Laboratory Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
 |
ABSTRACT |
The immune-mediated graft-versus-leukemia effect is important to prevent relapse after allogeneic progenitor cell transplantation. This process requires engraftment of donor immuno-competent cells. The objective of this study was to assess the feasibility of achieving engraftment of allogeneic peripheral blood or bone marrow progenitor cell after purine analog containing nonmyeloablative chemotherapy. Patients with advanced leukemia or myelodysplastic syndromes (MDS) who were not candidates for a conventional myeloablative therapy because of older age or organ dysfunction were eligible. All patients had an HLA-identical or one-antigen-mismatched related donor. Fifteen patients were treated (13 with acute myeloid leukemia and 2 with MDS). The median age was 59 years (range, 27 to 71 years). Twelve patients were either refractory to therapy or beyond first relapse. Eight patients received fludarabine at 30 mg/m2/d for 4 days with idarubicin at 12 mg/m2/d for 3 days and ara-c at 2 g/m2/d for 4 days (n = 7) or melphalan at 140 mg/m2/d (n = 1). Seven patients received 2-chloro-deoxyadenosine at 12 mg/m2/d for 5 days and ara-C 1 at g/m2/d for 5 days. Thirteen patients received allogeneic peripheral blood stem cells and 1 received bone marrow after chemotherapy. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methyl-prednisolone. Treatment was generally well tolerated, with only 1 death from multiorgan failure before receiving stem cells. Thirteen patients achieved a neutrophil count of greater than 0.5 × 109/L a median of 10 days postinfusion (range, 8 to 17 days). Ten patients achieved platelet counts of 20 × 109/L a median of 13 days after progenitor cell infusion (range, 7 to 78 days). Eight patients achieved complete remissions (bone marrow blasts were <5% with neutrophil recovery and platelet transfusion independence) that lasted a median of 60 days posttransplantation (range, 34 to 170+ days). Acute GVHD grade  2 occurred in 3 patients. Chimerism analysis of bone marrow cells in 6 of 8 patients achieving remission showed 90% donor cells between 14 and 30 days postinfusion, and 3 of 4 patients remaining in remission between 60 and 90 days continued to have 80% donor cells. We conclude that purine analog-containing nonmyeloablative regimens allow engraftment of HLA-compatible hematopoietic progenitor cells. This approach permits us to explore the graft-versus-leukemia effect without the toxicity of myeloablative therapy and warrants further study in patients with leukemia who are ineligible for conventional transplantation with myeloablative regimens either because of age or concurrent medical conditions.
| |
INTRODUCTION |
HIGH-DOSE CHEMO-radiotherapy with allogeneic bone marrow transplantation (BMT) has been extensively used to treat patients with hematologic malignancies.1,2 This procedure has generally been limited to younger patients in good general medical condition due to the increased risk of regimen related toxicities and graft-versus-host disease (GVHD) that occurs with age and poor performance status.3-8 Improvements in supportive care and GVHD prophylaxis have now enabled many centers to treat older patients, but few consider patients greater than 55 years of age.4,6 However, acute myeloid leukemia (AML) is most common in older adults. These patients have a poor prognosis and novel therapeutic options need to be explored.
The curative potential of allogeneic BMT is mediated in part by an immune mediated graft-versus-leukemia effect.9-14 Evidence supporting the graft-versus-leukemia effect includes a lower relapse rate in patients with GVHD and a higher risk of relapse after syngeneic or T-cell-depleted transplants.9-14 The most striking evidence for this phenomenon is the observation that infusions of donor lymphocytes can reinduce remissions in many patients.15 Patients with chronic myelogenous leukemia (CML) are most likely to respond, but selected patients with acute leukemia, chronic lymphocytic leukemia (CLL), myeloma, and lymphoma relapsing after allogeneic BMT have also responded.15-17 This finding suggests an alternative strategy of inducing graft-versus-leukemia after standard-dose nonablative chemotherapy as primary treatment for susceptible malignancies in patients ineligible for high-dose chemotherapy or total body irradiation.
The purine analogs fludarabine and 2-chlorodeoxyadenosine (2-CDA) have been shown to be active against a variety of hematologic malignancies.18 These compounds are also immunosuppressive, effectively inhibiting the mixed lymphocyte reaction in vitro.19,20
We performed a pilot trial to determine whether purine analog-containing nonmyeloablative chemotherapy could be sufficiently immunosuppressive to enable engraftment of allogeneic hematopoietic progenitor cells in patients considered ineligible for myeloablative therapy either because of age or medical condition.
| |
PATIENTS AND METHODS |
Eligibility criteria.
Patients between 55 and 70 years of age with acute leukemia or myelodysplasia beyond first complete remission were considered eligible for this study. Patients less than 55 years of age who were not eligible for a conventional myeloablative transplant protocol because of a concurrent medical condition were also eligible. Patients required an HLA-identical or one-antigen-mismatched related donor, a serum bilirubin level of less than 3.0 mg/dL, a serum creatinine level of less than 2.0 mg/dL, a cardiac ejection fraction of 40% or greater, and a Zubrod performance status of  2. Patients and donors signed written informed consents and the treatment was approved by the institutional review board.
Stem cell collection.
Donors received filgrastim at 6 µg/kg subcutaneously twice daily starting 4 to 5 days before the first collection. Leukaphereses were performed daily using conventional techniques for blood progenitor cell collection until greater than 3 × 106 CD34+ cells/kg recipient were collected.21 Donor cells were cryopreserved using standard techniques. If insufficient number of cells were collected or if peripheral blood stem cell collection was not feasible, donor bone marrow was harvested.
Chemotherapy.
Fifteen patients were treated. Seven patients without prior exposure to fludarabine received fludarabine at 30 mg/m2/d intravenously at the same time over 30 minutes for 4 days with either ara-C at 2 g/m2 administered intravenously over 4 hours starting 4 hours after the beginning of the fludarabine infusion and idarubicin at 12 mg/m2 intravenously for 3 days.22 One patient received the same fludarabine schedule with melphalan at 140 mg/m2 administered once at the end of chemotherapy. Seven patients with prior fludarabine exposure received ara-C at 1.0 g/m2/d over 2 hours intravenously for 5 days and 2-CDA at a dose of 12 mg/m2/d by continuous intravenous infusion for 5 days beginning 4 hours after the first dose of ara-C.23 Cells were infused 2 days after the last dose of chemotherapy.
Supportive care.
All patients were treated as inpatients in private rooms. Patients received antibacterial and antifungal prophylaxis with intravenous vancomycin at 1 g daily or oral penicillin at 250 mg four times daily in addition to norfloxacin at 400 mg orally twice daily and fluconazole at 200 mg/d. Broad spectrum antibiotics were begun for temperature greater than 38.3°C or clinical signs of infection.
Patients received filgrastim at 5 µg/kg/d from the day of the transplantation (day 0) until achievement of an absolute neutrophil count (ANC) of greater than 1.5 × 109/L. Hemoglobin was maintained at a level of 8 g/dL and the platelet count was maintained at 20 × 109/L with filtered and irradiated blood products.
GVHD prophylaxis consisted of cyclosporine at a dose of 3 mg/kg/d by continuous intravenous infusion changed to oral as soon as tolerated and methylprednisolone at 1.0 mg/kg/d beginning on day +5 tapered over the following 8 weeks. Patients without signs of GVHD on day 50 had their cyclosporine tapered by 10% to 20% weekly. Patients developing GVHD received methylprednisolone at 2 mg/kg/d intravenously and tapered upon response as tolerated.
Study endpoints.
The primary objectives of this study were to evaluate the engraftment potential and antileukemic effects of allogeneic hematopoietic progenitor cells in patients with acute leukemia or myelodysplastic syndromes (MDS) receiving intensive, but nonmyeloablative purine analog-containing chemotherapy. Chimerism and evidence of minimal residual disease were determined by conventional cytogenetics and restriction fragment length polymorphisms (RFLPs) using published techniques.24,25 Additional endpoints included toxicity as defined by the criteria of Bearman et al26 and hematologic recovery defined as the first of 3 consecutive days with an ANC greater than 0.5 × 109/L. Acute and chronic GVHD were scored according to standard criteria.27,28 Complete remission was defined as less than 5% blasts in bone marrow with normal maturation, an ANC greater than 1.5 × 109/L, and platelet transfusion independence. Survival was calculated as of August 8, 1996 from the day of transplantation according to the methods of Kaplan and Meier.29
| |
RESULTS |
Patient and disease characteristics.
From July 1995 to July 1996, 15 patients with acute leukemia or MDS were treated. Patient and disease characteristics are summarized in Table 1. In brief, the median age was 59 years (range, 27 to 71 years). Thirteen patients had AML (3 preceded by a prior hematologic disorder), 1 patient had chronic myelomonocytic leukemia (CMML), and 1 patient had refractory anemia with excess blasts in transformation (RAEB-T). The median time to transplantation from diagnosis was 391 days (range, 50 to 1,315 days). Nine patients were refractory to salvage chemotherapy, 3 patients were in untreated relapse (first, second, and third relapse), 1 patient was in a third remission, 1 patient had an untreated secondary AML 4 years after an autologous BMT, and the patient with CMML had received hydroxyurea chemotherapy. The median number of prior therapies was 2 (range, 0 to 4).
The median donor age was 57 years (range, 25 to 68 years). All donors were either fully HLA-compatible siblings (n = 13) or one-antigen-mismatched siblings (n = 2). Six donors were women and 9 were men; 6 donor-recipient pairs were sex-mismatched. Donors received a median of 5 days of treatment with filgrastim. Eight underwent one apheresis procedure and 5 required two procedures. The median CD34+ cell yield expressed as number of CD34+ cells per liter of blood processed during the first collection was 21.3 × 106 (range, 6.2 to 45.5 × 106). The median number of CD34+ cells infused was 4.5 × 106/kg (range, 1.7 to 9.9 × 106/kg).
Toxicity.
The chemotherapy was well tolerated in 13 of the 15 patients. One patient (unique patient no. [UPN] 1100), who had secondary AML and progressive pneumonia, died from multiorgan failure after the second dose of fludarabine, idarubicin, and ara-C. She developed progressive respiratory failure with renal and hepatic deterioration. Further chemotherapy was discontinued, and she died 48 hours later without receiving her donor cells. The only other instance of grade 3 toxicity was a patient with extensive anthracycline exposure and an ejection fraction of 54% before therapy (UPN 6108) who developed congestive heart failure that responded to diuretics and inotropic support.
Engraftment.
Thirteen patients achieved an ANC of greater than 0.5 × 109/L a median of 10 days posttransplantation (range, 8 to 17 days). One patient never cleared his peripheral blood blasts and failed to recover normal hematopoiesis. Ten patients achieved a platelet count of 20.0 × 109/L or greater without transfusions a median of 13 days postinfusion (range, 7 to 78 days).
GVHD.
Acute GVHD occurred in 3 patients, 1 limited to skin alone (grade 1) and the other 2 involving skin and gut (grade 2). GVHD responded to steroid therapy alone in 2 patients and required antithymocyte globulin in another. Chronic GVHD has not occurred, but only 5 patients are evaluable for this complication.
Response and chimerism.
Thirteen of 15 patients cleared their peripheral blood blasts. Eight patients achieved remission criteria, with 6 having 90% donor cells at that time (between days 14 and 30). One patient achieved remission criteria without evidence of donor cell engraftment by cytogenetics or RFLP, and 1 patient could not be assessed. Five patients relapsed between 43 and 127 days posttransplantation (median, 65 days). Responses and chimerism for each patient are shown in Tables 2 and 3.
Survival.
Six patients remain alive between 34 and 175 days posttransplantation (median, 100 days). Two patients remain in remission 34+ and 170+ days posttransplantation; the other 4 have active disease. None of the relapsing patients has responded to cyclosporine withdrawal or filgrastim therapy as treatment of relapse.30 The median survival was 78 days (range, 0 to 175+ days). The causes of death were leukemia (n = 5), infection after subsequent therapy (n = 2), multiorgan failure (n = 1), and aspergillosis (n = 1). The actuarial 100 day survival was 66% ± 19% for patients achieving a complete remission and 21% ± 17% for patients not achieving this response (P = .16 log rank).
| |
DISCUSSION |
Despite modern combination chemotherapy, most patients with acute leukemia relapse within the first 2 years of achieving complete remission. Durable responses to salvage therapy are rare, with 24% of patients expiring before achieving a response and approximately 33% achieving second remissions; the median survival is 18 weeks. The prognosis with conventional chemotherapy for second or third relapse is worse, with a median survival of 7 weeks and a complete remission rate of less than 10%.31
Myeloablative chemoradiotherapy with allogeneic progenitor cells can result in long-term disease-free survival in selected patients with advanced acute leukemia. This therapy is associated with substantial toxicity and the treatment-related mortality rate approaches 40%. This limits the use of transplantation therapies to younger patients with a relatively good performance status.1,2
The antileukemic effect seen with donor lymphocyte infusions in patients relapsing after allogeneic transplantation suggests that if engraftment of donor hematopoietic cells can be achieved after standard-dose chemotherapy, it may be possible to exploit the graft-versus-leukemia effect without the potential morbidity associated with myeloablative therapy.15,16
The purine analogs fludarabine and 2-CDA produce lymphocytopenia and substantial immunosuppression and could therefore enhance engraftment of allogeneic hematopoietic progenitors.18-20 Fludarabine and 2-CDA combinations have been extensively studied in combination with ara-C as salvage therapy for patients with acute leukemia.22,23 The addition of allogeneic hematopoietic progenitor cells could potentially enhance hematopoietic recovery as well as provide a graft-versus-leukemia effect. The presence of stable chimerism would allow subsequent donor lymphocyte infusions in patients with minimal residual disease or a high likelihood of relapse.
This study examined the feasibility of this approach in poor prognosis patients with recurrent or resistent AML or MDS who were not eligible for myeloablative therapy because of advanced age or concomitant medical illness. Thirteen patients recovered granulocytes between 8 and 17 days postinfusion (15 to 24 days after the beginning of chemotherapy), with 6 patients in remission with predominantly donor cells. Moreover, 3 patients in remission 60 to 90 days postinfusion had 80% donor cells as assessed by cytogenetics or RFLP. We did not perform studies concerning lineage-specific engraftments and the extent of lymphoid engraftment is unknown. Longer follow-up and specific assays for chimerism in each lineage are required for evaluation of the extent and durability of engraftment. In this study, the durability of the graft was difficult to assess in our patients due to the fact that many of them had recurrent leukemia within a short period of time. However, the observation that 3 of 4 patients in remission had predominantly donor cells between 2 and 3 months posttransplantation without other signs of graft failure suggests the possibility of durable engraftment in some patients.
We were unable to demonstrate the feasibility or efficacy of donor lymphocyte infusions for treating relapse in this setting because many patients relapsed quickly after transplantation with rapidly progressive disease. However, this study suggests that a strategy of purine analog-containing nonmyeloablative chemotherapy followed by infusion of donor lymphocytes for patients with evidence of minimal residual disease or with a high risk of relapse could be feasible in patients with less advanced hematologic malignancies. Such a strategy may be particularly useful for patients with CML, multiple myeloma, or acute leukemia in first remission who have an HLA-compatible donor but are deemed ineligible for a conventional myeloablative preparative regimen due to their age or medical condition.
Many other potential applications exist for a nonmyeloablative regimen that can consistently achieve engraftment of allogeneic hematopoietic progenitor cells. These include treatment of nonmalignant hematologic disorders or of immune or metabolic diseases or induction of tolerance for solid organ transplantation. The results of this study suggest that purine analog-containing nonmyeloablative regimens should be explored in these settings.
In summary, this study shows that purine analog-containing nonmyeloablative chemotherapy followed by allogeneic hematopoietic progenitor cells is feasible in elderly or debilitated patients with advanced leukemia. This therapy can result in engraftment of donor cells with rapid hematologic recovery and little regimen-related toxicity. Further studies with a larger number of patients and longer follow-up will be necessary to determine if this approach will be associated with an acceptable risk of acute and chronic GVHD and if further infusions of donor lymphocytes for treatment of minimal residual disease or as relapse prevention will improve leukemia-free survival in these patients or in patients with less advanced disease. Further exploration of this strategy as alternative therapy for patients with hematologic malignancies who have an HLA-compatible donor but are ineligible for a conventional myeloablative therapy is warranted.
| |
FOOTNOTES |
Submitted October 7, 1996;
accepted February 5, 1997.
Supported in part by National Cancer Institute Grant No. CA55164-05.
Address reprint requests to Sergio Giralt, MD, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hearly marked
``advertisment'' in accordance with 18 U.S.C. section 1734 solely to
indicate this fact.
| |
ACKNOWLEDGMENT |
The authors acknowledge the contributions of the nurses, fellows, pharm D's, and laboratory technicians at the M.D. Anderson Cancer Center, whose invaluable assistance and dedication to excellent and compassionate patient care made this work possible.
| |
REFERENCES |
1.
Bortin M,
Horowitz M,
Rimm A:
Increasing utilization of allogeneic bone marrow transplantation: Results of the 1988-1990 survey.
Ann Intern Med
116:505,
1992
2.
Bortin M,
Horowitz M,
Gale R,
Barrett J,
Champlin R,
Dicke K,
Gluckman E,
Kolb H,
Marmont A,
Mrsic M,
Sobocinski K,
Weiner R,
Rimm A:
Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980's.
JAMA
268:607,
1992[Abstract/Free Full Text]
3. Clift R, Appelbaum F, Thomas E. Bone marrow transplantation for chronic myelogenous leukemia. Blood 83:2752, 1994
4.
Klingemann HG,
Storb R,
Fefer A,
Deeg HJ,
Appelbaum F,
Buckner CD,
Cheever MA,
Greenberg PD,
Stewart PS,
Sullivan KM,
Witherspoon RP,
Thomas ED:
Bone marrow transplantation in patients aged 45 years and older.
Blood
65:770,
1986
5.
Blume KG,
Forman SJ,
Nademanee AP,
O'Donnell MR,
Snyder DS,
Fahey JL,
Findley DO,
Lipsett JA,
Zaia JA,
Metter GE,
Hill LR:
Bone marrow transplantation for hematologic malignancies in patients aged 30 years or older.
J Clin Oncol
4:1489,
1986[Abstract/Free Full Text]
6.
Ringden O,
Horowitz MH,
Gale RP,
Biggs JC,
Gajewski J,
Rimm AA,
Speck B,
Veum-Stone JA,
de Witte T,
Bortin MM:
Outcome after allogeneic bone marrow transplant for leukemia in older patients.
JAMA
270:57,
1993[Abstract/Free Full Text]
7.
Keating S,
Suciu S,
de Witte T,
Mandelli F,
Willemze R,
Resegotti L,
Broccia G,
Thaler J,
Labar B,
Damasio E,
Bizzi B,
Rotoli B,
Vekhoff A,
Muus P,
Petti MC,
Dardenne M,
Solbu G,
Vegna ML,
Zittoun RA,
for the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologische Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups:
Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: An analysis of the EORTC-GIMEMA AML 8A trial.
Bone Marrow Transplant
17:993,
1996[Medline]
[Order article via Infotrieve]
8.
Gorin NC,
Labopin M,
Fouillard L,
Meloni G,
Frassoni F,
Iriondo A,
Brunet-Mauri S,
Goldstone AH,
Harousseau JL,
Reiffers J,
Esperou-Bourdeau H,
Gluckman E:
Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Group for Blood and Marrow Transplantation (EBMT).
Bone Marrow Transplant
18:111,
1996[Medline]
[Order article via Infotrieve]
9.
Sullivan K,
Weiden P,
Storb R,
Witherspoon R,
Fefer A,
Fisher L,
Buckner C,
Anasetti C,
Appelbaum F,
Badger C,
Beatty P,
Bensinger W,
Berenson R,
Bigelow C,
Cheeves M,
Clift R,
Deeg H,
Doney K,
Greenberg P,
Hansen J,
Hill R,
Longhran T,
Martin P,
Neiman P,
Peterson F,
Sanders J,
Singer J,
Stewart P,
Thomas E:
Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia.
Blood
73:1720,
1989[Abstract/Free Full Text]
10.
Weiden P,
Flournoy N,
Thomas E,
Prentice R,
Fefer A,
Buckner C,
Storb R:
Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts.
N Engl J Med
300:1068,
1979[Abstract]
11.
Weiden P,
Sullivan K,
Flournoy N,
Storb R,
Thomas E:
Antileukemic effect of chronic graft-versus-host disease: Contributions to improved survival after allogeneic marrow transplantation.
N Engl J Med
304:1529,
1981[Medline]
[Order article via Infotrieve]
12.
Horowitz M,
Gale R,
Sondel M,
Goldman J,
Kersey J,
Kolb H,
Rimm A,
Ringden O,
Rozman C,
Speck B,
Truitt R,
Zwaan F,
Bortin M:
Graft-versus-leukemia reactions after bone marrow transplantation.
Blood
75:555,
1990[Abstract/Free Full Text]
13.
Goldman J,
Gale R,
Horowitz M,
Biggs J,
Champlin R,
Gluckman E,
Hoffmann R,
Jacobsen S,
Marmont A,
McGlave P,
Messner H,
Rimm A,
Rozman C,
Speck B,
Weiner R,
Bortin M:
Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T-cell depletion.
Ann Intern Med
108:806,
1988
14.
Gale RP,
Horowitz MM,
Ash RC,
Champlin RE,
Goldman JM,
Rimm AA,
Ringden O,
Veum Stone JA,
Bortin MM:
Identical-twin bone marrow transplants for leukemia.
Ann Intern Med
120:646,
1994[Abstract/Free Full Text]
15.
Kolb HJ,
Schattenberg A,
Goldman JM,
Hertenstein B,
Jacobsen N,
Arcese W,
Ljungman P,
Ferrant A,
Verdonck L,
Niederwieser D,
van Rhee F,
Mittermuller J,
de Witte T,
Holler E,
Ansari H:
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.
Blood
86:2041,
1995[Abstract/Free Full Text]
16. Collins R, Shpilberg O, Drobyski W, Porter D, Antin J, Wolff S, Giralt S, Chetrit A, Ognoskie N, Prine S, Nemunaitis J: Donor leukocyte infusion (DLI) for post-bone marrow transplant (BMT) relapse-retrospective cohort analysis of 141 cases. Blood 86:563a, 1995 (abstr, suppl 1)
17.
Rondón G,
Giralt S,
Huh Y,
Khouri I,
Andersson B,
Andreeff M,
Champlin R:
Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia.
Bone Marrow Transplant
18:669,
1996[Medline]
[Order article via Infotrieve]
18.
Plunkett W,
Sanders PP:
Metabolism and action of purine nucleoside analogs.
Pharmacol Ther
49:239,
1991[Medline]
[Order article via Infotrieve]
19.
Goodman ER,
Fiedor PS,
Fein S,
Sung RS,
Athan E,
Hardy MA:
Fludarabine phosphate and 2-chlorodeoxyadenosine: Immunosuppressive DNA synthesis inhibitors with potential application in islet allo-xenotransplantation.
Transplant Proc
27:3293,
1995[Medline]
[Order article via Infotrieve]
20.
Gorski A,
Grieb P,
Korczak-Kowalska G,
Wierzbicki P,
Stepien-Sopniewska B,
Mrowiec T:
Cladribine (2-chloro-deoxyadenosine, CDA): An inhibitor of human B and T cell activation in vitro.
Immunopharmacology
26:197,
1993[Medline]
[Order article via Infotrieve]
21.
Anderlini P,
Przepiorka D,
Seong D,
Miller P,
Sundberg J,
Lichtiger B,
Norfleet F,
Chan KW,
Champlin R,
Körbling M:
Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures.
Transfusion
36:596,
1996[Medline]
[Order article via Infotrieve]
22.
Estey E,
Plunkett W,
Gandhi V,
Rios MB,
Kantarjian H,
Keating MJ:
Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.
Leuk Lymphoma
9:343,
1993[Medline]
[Order article via Infotrieve]
23.
Kornblau S,
Andreeff M,
Beran M,
Escudier S,
Kantarjian H,
Koller C,
O'Brien S,
Robertson LE,
Estey E:
2-CDA ± Ara-C is ineffective therapy for relapsed or refractory AML in adults.
Proc Am Soc Clin Oncol
14:336,
1995
24.
Standing Committee on Human Cytogenetic Nomenclature:
An international system for human cytogenetic nomenclature 20 (1978 ISCN).
Cytogenet Cell Genet
21:309,
1978[Medline]
[Order article via Infotrieve]
25.
Yam P,
Petz L,
Knowlton R,
Wallace R,
Stock A,
DeLange G,
Brown V,
Doris-Keller H,
Blume K:
Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation.
Transplantation
43:399,
1987[Medline]
[Order article via Infotrieve]
26.
Bearman SI,
Appelbaum FR,
Buckner CD,
Petersen FB,
Fisher LD,
Clift RA,
Thomas ED:
Regimen related toxicities in patients undergoing bone marrow transplantation.
J Clin Oncol
6:1562,
1988[Abstract/Free Full Text]
27.
Glucksberg H,
Storb R,
Fefer A,
Buckner CD,
Neiman PE,
Clift RA,
Lerner KG,
Thomas ED:
Clinical manifestations of graft versus host disease in human recipients of marrow from HLA matched sibling donors.
Transplantation
18:295,
1974[Medline]
[Order article via Infotrieve]
28.
Schulman HM,
Sullivan KM,
Weiden PL,
McDonald GB,
Striker GE,
Sale GE,
Hackman R,
Tsoi MS,
Storb R,
Thomas ED:
Chronic graft-versus-host disease syndrome in man. A long term clinical pathologic study of 20 Seattle patients.
Am J Med
69:204,
1980[Medline]
[Order article via Infotrieve]
29.
Kaplan E,
Meier P:
Nonparametric estimation from incomplete observations.
J Am Stat Assoc
53:457,
1958
30.
Giralt SA,
Champlin RE:
Leukemia relapse after allogeneic bone marrow transplantation: A review.
Blood
84:3603,
1994[Free Full Text]
31.
Keating M,
Kantarjian H,
Smith T,
Estey E,
Walters R,
Andersson B,
Beran M,
McCredie K,
Freireich E:
Response to salvage therapy and survival after relapse in acute myelogenous leukemia.
J Clin Oncol
7:1071,
1989[Abstract]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. Ishiyama, A. Takami, S. Suzuki, H. Konaka, M. Namiki, A. Ooi, and S. Nakao
Relationship Between Tumor-infiltrating T Lymphocytes and Clinical Response After Reduced-intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Renal Cell Carcinoma: A Single Center Prospective Study
Jpn. J. Clin. Oncol.,
December 1, 2009;
39(12):
807 - 812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Ringden, M. Labopin, G. Ehninger, D. Niederwieser, R. Olsson, N. Basara, J. Finke, R. Schwerdtfeger, M. Eder, D. Bunjes, et al.
Reduced Intensity Conditioning Compared With Myeloablative Conditioning Using Unrelated Donor Transplants in Patients With Acute Myeloid Leukemia
J. Clin. Oncol.,
September 20, 2009;
27(27):
4570 - 4577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. T. Schiffer, K. Kirby, B. Sandmaier, R. Storb, L. Corey, and M. Boeckh
Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation
Haematologica,
August 1, 2009;
94(8):
1101 - 1108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Thomson, E. C. Morris, A. Bloor, G. Cook, D. Milligan, A. Parker, F. Clark, L. Yung, D. C. Linch, R. Chakraverty, et al.
Favorable Long-Term Survival After Reduced-Intensity Allogeneic Transplantation for Multiple-Relapse Aggressive Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
January 20, 2009;
27(3):
426 - 432.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. L. Weissman and J. A. Shizuru
The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases
Blood,
November 1, 2008;
112(9):
3543 - 3553.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Valcarcel, R. Martino, D. Caballero, J. Martin, C. Ferra, J. B. Nieto, A. Sampol, M. T. Bernal, J. L. Pinana, L. Vazquez, et al.
Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival
J. Clin. Oncol.,
February 1, 2008;
26(4):
577 - 584.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sureda, S. Robinson, C. Canals, A. M. Carella, M. A. Boogaerts, D. Caballero, A. E. Hunter, L. Kanz, S. Slavin, J. J. Cornelissen, et al.
Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
J. Clin. Oncol.,
January 20, 2008;
26(3):
455 - 462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Olavarria, S. Siddique, M. J. Griffiths, S. Avery, J. L. Byrne, K. P. Piper, A. L. Lennard, L. Pallan, J. M. Arrazi, J. B. Perz, et al.
Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia
Blood,
December 15, 2007;
110(13):
4614 - 4617.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kebriaei, M. A. Detry, S. Giralt, A. Carrasco-Yalan, A. Anagnostopoulos, D. Couriel, I. F. Khouri, P. Anderlini, C. Hosing, A. Alousi, et al.
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia
Blood,
November 1, 2007;
110(9):
3456 - 3462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Locatelli, M. Zecca, A. Pession, G. Morreale, D. Longoni, P. Di Bartolomeo, F. Porta, F. Fagioli, B. Nobili, M. E. Bernardo, et al.
The outcome of children with Fanconi anemia given hematopoietic stem cell transplantation and the influence of fludarabine in the conditioning regimen: a report from the Italian pediatric group
Haematologica,
October 1, 2007;
92(10):
1381 - 1388.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Hehlmann, U. Berger, M. Pfirrmann, H. Heimpel, A. Hochhaus, J. Hasford, H.-J. Kolb, T. Lahaye, O. Maywald, A. Reiter, et al.
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia
Blood,
June 1, 2007;
109(11):
4686 - 4692.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. Pillai, T. I. George, S. Dutt, P. Teo, and S. Strober
Host NKT Cells Can Prevent Graft-versus-Host Disease and Permit Graft Antitumor Activity after Bone Marrow Transplantation
J. Immunol.,
May 15, 2007;
178(10):
6242 - 6251.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Crawley, S. Iacobelli, B. Bjorkstrand, J. F. Apperley, D. Niederwieser, G. Gahrton, and for the Chronic Leukaemia Working Party of the Eur
Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning
Blood,
April 15, 2007;
109(8):
3588 - 3594.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Rizzieri, L. P. Koh, G. D. Long, C. Gasparetto, K. M. Sullivan, M. Horwitz, J. Chute, C. Smith, J. Z. Gong, A. Lagoo, et al.
Partially Matched, Nonmyeloablative Allogeneic Transplantation: Clinical Outcomes and Immune Reconstitution
J. Clin. Oncol.,
February 20, 2007;
25(6):
690 - 697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Estey, M. de Lima, R. Tibes, S. Pierce, H. Kantarjian, R. Champlin, and S. Giralt
Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
Blood,
February 15, 2007;
109(4):
1395 - 1400.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Baron, R. Storb, B. E. Storer, M. B. Maris, D. Niederwieser, J. A. Shizuru, T. R. Chauncey, B. Bruno, S. J. Forman, P. A. McSweeney, et al.
Factors Associated With Outcomes in Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning After Failed Myeloablative Hematopoietic Cell Transplantation
J. Clin. Oncol.,
September 1, 2006;
24(25):
4150 - 4157.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N.-C. Gorin, M. Labopin, J.-M. Boiron, N. Theorin, T. Littlewood, S. Slavin, H. Greinix, J. Y. Cahn, E. P. Alessandrino, A. Rambaldi, et al.
Results of Genoidentical Hemopoietic Stem Cell Transplantation With Reduced Intensity Conditioning for Acute Myelocytic Leukemia: Higher Doses of Stem Cells Infused Benefit Patients Receiving Transplants in Second Remission or Beyond--The Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation
J. Clin. Oncol.,
August 20, 2006;
24(24):
3959 - 3966.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Barkholt, M. Bregni, M. Remberger, D. Blaise, J. Peccatori, G. Massenkeil, P. Pedrazzoli, A. Zambelli, J.-O. Bay, S. Francois, et al.
Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe
Ann. Onc.,
July 1, 2006;
17(7):
1134 - 1140.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Jabbour, E. Estey, and H. M. Kantarjian
Adult Acute Myeloid Leukemia
Mayo Clin. Proc.,
February 1, 2006;
81(2):
247 - 260.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Locatelli
Reduced-Intensity Regimens in Allogeneic Hematopoietic Stem Cell Transplantation for Hemoglobinopathies
Hematology,
January 1, 2006;
2006(1):
398 - 401.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. L. Abbott
Chronic Lymphocytic Leukemia: Recent Advances in Diagnosis and Treatment
Oncologist,
January 1, 2006;
11(1):
21 - 30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Giaccone, J. S. McCune, M. B. Maris, T. A. Gooley, B. M. Sandmaier, J. T. Slattery, S. Cole, R. A. Nash, R. F. Storb, and G. E. Georges
Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation
Blood,
December 15, 2005;
106(13):
4381 - 4388.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mohty, D. Blaise, C. Faucher, N. Vey, R. Bouabdallah, A.-M. Stoppa, F. Viret, G. Gravis, D. Olive, and B. Gaugler
Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation
Blood,
December 15, 2005;
106(13):
4407 - 4411.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Caballero, J. A. Garcia-Marco, R. Martino, V. Mateos, J. M. Ribera, J. Sarra, A. Leon, G. Sanz, J. de la Serna, R. Cabrera, et al.
Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q- and 17p-)
Clin. Cancer Res.,
November 1, 2005;
11(21):
7757 - 7763.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Crawley, R. Szydlo, M. Lalancette, A. Bacigalupo, A. Lange, M. Brune, G. Juliusson, A. Nagler, A. Gratwohl, J. Passweg, et al.
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT
Blood,
November 1, 2005;
106(9):
2969 - 2976.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Stelljes, M. Bornhauser, M. Kroger, J. Beyer, M. C. Sauerland, A. Heinecke, B. Berning, C. Scheffold, G. Silling, T. Buchner, et al.
Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
Blood,
November 1, 2005;
106(9):
3314 - 3321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Corradini, F. Zallio, J. Mariotti, L. Farina, M. Bregni, P. Valagussa, F. Ciceri, A. Bacigalupo, A. Dodero, M. Lucesole, et al.
Effect of Age and Previous Autologous Transplantation on Nonrelapse Mortality and Survival in Patients Treated With Reduced-Intensity Conditioning and Allografting for Advanced Hematologic Malignancies
J. Clin. Oncol.,
September 20, 2005;
23(27):
6690 - 6698.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-T. Rubio, T. I. Saito, K. Kattleman, G. Zhao, J. Buchli, and M. Sykes
Mechanisms of the Antitumor Responses and Host-versus-Graft Reactions Induced by Recipient Leukocyte Infusions in Mixed Chimeras Prepared with Nonmyeloablative Conditioning: A Critical Role for Recipient CD4+ T Cells and Recipient Leukocyte Infusion-Derived IFN-{gamma}-Producing CD8+ T Cells
J. Immunol.,
July 15, 2005;
175(2):
665 - 676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Crawley, M. Lalancette, R. Szydlo, M. Gilleece, K. Peggs, S. Mackinnon, G. Juliusson, L. Ahlberg, A. Nagler, A. Shimoni, et al.
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT
Blood,
June 1, 2005;
105(11):
4532 - 4539.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Girgis, C. Hallemeier, W. Blum, R. Brown, H.-s. Lin, H. Khoury, L. T. Goodnough, R. Vij, S. Devine, M. Wehde, et al.
Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide
Blood,
April 15, 2005;
105(8):
3035 - 3041.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Baron, M. B. Maris, B. M. Sandmaier, B. E. Storer, M. Sorror, R. Diaconescu, A. E. Woolfrey, T. R. Chauncey, M. E.D. Flowers, M. Mielcarek, et al.
Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning
J. Clin. Oncol.,
March 20, 2005;
23(9):
1993 - 2003.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. P. Alyea, H. T. Kim, V. Ho, C. Cutler, J. Gribben, D. J. DeAngelo, S. J. Lee, S. Windawi, J. Ritz, R. M. Stone, et al.
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age
Blood,
February 15, 2005;
105(4):
1810 - 1814.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Rao, P. J. Amrolia, A. Jones, C. M. Cale, P. Naik, D. King, G. E. Davies, H. B. Gaspar, and P. A. Veys
Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen
Blood,
January 15, 2005;
105(2):
879 - 885.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Giralt
Reduced-Intensity Conditioning Regimens for Hematologic Malignancies: What Have We Learned over the Last 10 Years?
Hematology,
January 1, 2005;
2005(1):
384 - 389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Baron, J. E. Baker, R. Storb, T. A. Gooley, B. M. Sandmaier, M. B. Maris, D. G. Maloney, S. Heimfeld, D. Oparin, E. Zellmer, et al.
Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
Blood,
October 15, 2004;
104(8):
2254 - 2262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Takahashi and R. W. Childs
Nonmyeloablative Transplantation: An Allogeneic-Based Immunotherapy for Renal Cell Carcinoma
Clin. Cancer Res.,
September 15, 2004;
10(18):
6353S - 6359S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Y. L. Ho, A. Pagliuca, M. Kenyon, J. E. Parker, A. Mijovic, S. Devereux, and G. J. Mufti
Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning
Blood,
September 15, 2004;
104(6):
1616 - 1623.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. de Lima, A. Anagnostopoulos, M. Munsell, M. Shahjahan, N. Ueno, C. Ippoliti, B. S. Andersson, J. Gajewski, D. Couriel, J. Cortes, et al.
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation
Blood,
August 1, 2004;
104(3):
865 - 872.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Miyakoshi, K. Yuji, M. Kami, E. Kusumi, Y. Kishi, K. Kobayashi, N. Murashige, T. Hamaki, S.-W. Kim, J.-i. Ueyama, et al.
Successful Engraftment After Reduced-Intensity Umbilical Cord Blood Transplantation for Adult Patients with Advanced Hematological Diseases
Clin. Cancer Res.,
June 1, 2004;
10(11):
3586 - 3592.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Leger and T. J. Nevill
Hematopoietic stem cell transplantation: a primer for the primary care physician
Can. Med. Assoc. J.,
May 11, 2004;
170(10):
1569 - 1577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Y. Mapara and M. Sykes
Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance
J. Clin. Oncol.,
March 15, 2004;
22(6):
1136 - 1151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Carvallo, N. Geller, R. Kurlander, R. Srinivasan, O. Mena, T. Igarashi, L. M. Griffith, W. M. Linehan, and R. W. Childs
Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors
Blood,
February 15, 2004;
103(4):
1560 - 1563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Faulkner, C. Craddock, J. L. Byrne, P. Mahendra, A. P. Haynes, H. G. Prentice, M. Potter, A. Pagliuca, A. Ho, S. Devereux, et al.
BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients
Blood,
January 15, 2004;
103(2):
428 - 434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Blaise, J. O. Bay, C. Faucher, M. Michallet, J.-M. Boiron, B. Choufi, J.-Y. Cahn, N. Gratecos, J.-J. Sotto, S. Francois, et al.
Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors
Blood,
January 15, 2004;
103(2):
435 - 441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Casper, W. Knauf, T. Kiefer, D. Wolff, B. Steiner, U. Hammer, R. Wegener, H.-D. Kleine, S. Wilhelm, A. Knopp, et al.
Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation
Blood,
January 15, 2004;
103(2):
725 - 731.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Hogan, M. Maris, B. Storer, B. M. Sandmaier, D. G. Maloney, H. G. Schoch, A. E. Woolfrey, H. M. Shulman, R. Storb, and G. B. McDonald
Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients
Blood,
January 1, 2004;
103(1):
78 - 84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. T. Ueno, Y. C. Cheng, G. Rondon, N. M. Tannir, J. L. Gajewski, D. R. Couriel, C. Hosing, M. J. de Lima, P. Anderlini, I. F. Khouri, et al.
Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors
Blood,
November 15, 2003;
102(10):
3829 - 3836.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Fukuda, R. C. Hackman, K. A. Guthrie, B. M. Sandmaier, M. Boeckh, M. B. Maris, D. G. Maloney, H. J. Deeg, P. J. Martin, R. F. Storb, et al.
Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation
Blood,
October 15, 2003;
102(8):
2777 - 2785.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Wong, S. A. Giralt, T. Martin, D. R. Couriel, A. Anagnostopoulos, C. Hosing, B. S. Andersson, P. Cano, M. Shahjahan, C. Ippoliti, et al.
Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years
Blood,
October 15, 2003;
102(8):
3052 - 3059.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Bachar-Lustig, S. Reich-Zeliger, and Y. Reisner
Anti-third-party veto CTLs overcome rejection of hematopoietic allografts: synergism with rapamycin and BM cell dose
Blood,
September 15, 2003;
102(6):
1943 - 1950.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-T. Rubio, Y.-M. Kim, T. Sachs, M. Mapara, G. Zhao, and M. Sykes
Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-{gamma}
Blood,
September 15, 2003;
102(6):
2300 - 2307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Barker, D. J. Weisdorf, T. E. DeFor, B. R. Blazar, J. S. Miller, and J. E. Wagner
Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning
Blood,
September 1, 2003;
102(5):
1915 - 1919.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. Rad, G. Pollara, S. M. A. Sohaib, C. Chiang, B. M. Chain, and D. R. Katz
The Differential Influence of Allogeneic Tumor Cell Death via DNA Damage on Dendritic Cell Maturation and Antigen Presentation
Cancer Res.,
August 15, 2003;
63(16):
5143 - 5150.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.C. Taussig, A.J. Davies, J.D. Cavenagh, H. Oakervee, D. Syndercombe-Court, S. Kelsey, J.A.L. Amess, A.Z.S. Rohatiner, T.A. Lister, and M.J. Barnett
Durable Remissions of Myelodysplastic Syndrome and Acute Myeloid Leukemia After Reduced-Intensity Allografting
J. Clin. Oncol.,
August 15, 2003;
21(16):
3060 - 3065.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bornhauser, B. Storer, J. T. Slattery, F. R. Appelbaum, H. J. Deeg, J. Hansen, P. J. Martin, G. B. McDonald, W. G. Nichols, J. Radich, et al.
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells
Blood,
August 1, 2003;
102(3):
820 - 826.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Fukuda, M. Boeckh, R. A. Carter, B. M. Sandmaier, M. B. Maris, D. G. Maloney, P. J. Martin, R. F. Storb, and K. A. Marr
Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning
Blood,
August 1, 2003;
102(3):
827 - 833.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mohty, J.-O. Bay, C. Faucher, B. Choufi, K. Bilger, O. Tournilhac, N. Vey, A.-M. Stoppa, D. Coso, C. Chabannon, et al.
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen
Blood,
July 15, 2003;
102(2):
470 - 476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Billiau, S. Fevery, O. Rutgeerts, W. Landuyt, and M. Waer
Transient expansion of Mac1+Ly6-G+Ly6-C+ early myeloid cells with suppressor activity in spleens of murine radiation marrow chimeras: possible implications for the graft-versus-host and graft-versus-leukemia reactivity of donor lymphocyte infusions
Blood,
July 15, 2003;
102(2):
740 - 748.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mielcarek, P. J. Martin, W. Leisenring, M. E. D. Flowers, D. G. Maloney, B. M. Sandmaier, M. B. Maris, and R. Storb
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation
Blood,
July 15, 2003;
102(2):
756 - 762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C. Morris, P. Rebello, K. J. Thomson, K. S. Peggs, C. Kyriakou, A. H. Goldstone, S. Mackinnon, and G. Hale
Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications
Blood,
July 1, 2003;
102(1):
404 - 406.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Bertz, K. Potthoff, and J. Finke
Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors in Older Patients With Myeloid Leukemia
J. Clin. Oncol.,
April 15, 2003;
21(8):
1480 - 1484.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Or, M. Y. Shapira, I. Resnick, A. Amar, A. Ackerstein, S. Samuel, M. Aker, E. Naparstek, A. Nagler, and S. Slavin
Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase
Blood,
January 15, 2003;
101(2):
441 - 445.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Uzunel, J. Mattsson, M. Brune, J.-E. Johansson, J. Aschan, and O. Ringden
Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation
Blood,
January 15, 2003;
101(2):
469 - 472.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Locatelli, G. Rossi, and C. Balduini
Hematopoietic Stem-Cell Transplantation for the Bernard-Soulier Syndrome
Ann Intern Med,
January 7, 2003;
138(1):
79 - 79.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Mufti, A. F. List, S. D. Gore, and A. Y.L. Ho
Myelodysplastic Syndrome
Hematology,
January 1, 2003;
2003(1):
176 - 199.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. F. Storb, G. Lucarelli, P. A. McSweeney, and R. W. Childs
Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors
Hematology,
January 1, 2003;
2003(1):
372 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Robinson, A. H. Goldstone, S. Mackinnon, A. Carella, N. Russell, C. R. de Elvira, G. Taghipour, and N. Schmitz
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation
Blood,
December 15, 2002;
100(13):
4310 - 4316.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Kroger, H. G. Sayer, R. Schwerdtfeger, M. Kiehl, A. Nagler, H. Renges, T. Zabelina, B. Fehse, F. Ayuk, G. Wittkowsky, et al.
Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality
Blood,
December 1, 2002;
100(12):
3919 - 3924.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Perez-Simon, P. D. Kottaridis, R. Martino, C. Craddock, D. Caballero, R. Chopra, J. Garcia-Conde, D. W. Milligan, S. Schey, A. Urbano-Ispizua, et al.
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders
Blood,
October 16, 2002;
100(9):
3121 - 3127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Martino, M. D. Caballero, J. A. Perez Simon, C. Canals, C. Solano, A. Urbano-Ispizua, J. Bargay, A. Leon, J. Sarra, G. F. Sanz, et al.
Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes
Blood,
August 28, 2002;
100(6):
2243 - 2245.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Billiau, S. Fevery, O. Rutgeerts, W. Landuyt, and M. Waer
Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants
Blood,
August 13, 2002;
100(5):
1894 - 1902.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Kroger, R. Schwerdtfeger, M. Kiehl, H. G. Sayer, H. Renges, T. Zabelina, B. Fehse, F. Togel, G. Wittkowsky, R. Kuse, et al.
Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma
Blood,
July 18, 2002;
100(3):
755 - 760.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Ballen, P. S. Becker, R. V. B. Emmons, T. J. Fitzgerald, C. C. Hsieh, Q. Liu, C. Heyes, Y. Clark, W. Levy, J. F. Lambert, et al.
Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy
Blood,
June 28, 2002;
100(2):
442 - 450.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Forman, R. M. Welsh, T. G. Markees, B. A. Woda, J. P. Mordes, A. A. Rossini, and D. L. Greiner
Viral Abrogation of Stem Cell Transplantation Tolerance Causes Graft Rejection and Host Death by Different Mechanisms
J. Immunol.,
June 15, 2002;
168(12):
6047 - 6056.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Chakrabarti, S. Mackinnon, R. Chopra, P. D. Kottaridis, K. Peggs, P. O'Gorman, R. Chakraverty, T. Marshall, H. Osman, P. Mahendra, et al.
High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution
Blood,
May 29, 2002;
99(12):
4357 - 4363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Alizadeh, M. Bernard, B. Danic, C. Dauriac, B. Birebent, C. Lapart, T. Lamy, P.-Y. Le Prise, A. Beauplet, D. Bories, et al.
Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction
Blood,
May 29, 2002;
99(12):
4618 - 4625.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Saito, Y. Kanda, M. Kami, K. Kato, N. Shoji, S. Kanai, T. Ohnishi, Y. Kawano, K. Nakai, T. Ogasawara, et al.
Therapeutic Potential of a Reduced-Intensity Preparative Regimen for Allogeneic Transplantation with Cladribine, Busulfan, and Antithymocyte Globulin against Advanced/Refractory Acute Leukemia/Lymphoma
Clin. Cancer Res.,
April 1, 2002;
8(4):
1014 - 1020.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Klangsinsirikul, G. I. Carter, J. L. Byrne, G. Hale, and N. H. Russell
Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution
Blood,
April 1, 2002;
99(7):
2586 - 2591.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Junghanss, M. Boeckh, R. A. Carter, B. M. Sandmaier, M. B. Maris, D. G. Maloney, T. Chauncey, P. A. McSweeney, M.-T. Little, L. Corey, et al.
Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study
Blood,
March 15, 2002;
99(6):
1978 - 1985.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Devine, R. Hoffman, A. Verma, R. Shah, B. A. Bradlow, W. Stock, V. Maynard, E. Jessop, D. Peace, M. Huml, et al.
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia
Blood,
March 15, 2002;
99(6):
2255 - 2258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Korbling, R. L. Katz, A. Khanna, A. C. Ruifrok, G. Rondon, M. Albitar, R. E. Champlin, and Z. Estrov
Hepatocytes and Epithelial Cells of Donor Origin in Recipients of Peripheral-Blood Stem Cells
N. Engl. J. Med.,
March 7, 2002;
346(10):
738 - 746.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Kang, M. de Witte, H. Malech, R. A. Morgan, S. Phang, C. Carter, S. F. Leitman, R. Childs, A. J. Barrett, R. Little, et al.
Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome
Blood,
January 15, 2002;
99(2):
698 - 701.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. Greenberg, N. S. Young, and N. Gattermann
Myelodysplastic Syndromes
Hematology,
January 1, 2002;
2002(1):
136 - 161.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. G. Maloney, B. M. Sandmaier, S. Mackinnon, and J. A. Shizuru
Non-Myeloablative Transplantation
Hematology,
January 1, 2002;
2002(1):
392 - 421.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. Corradini, C. Tarella, A. Olivieri, A. M. Gianni, C. Voena, F. Zallio, M. Ladetto, M. Falda, M. Lucesole, A. Dodero, et al.
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies
Blood,
January 1, 2002;
99(1):
75 - 82.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Weissinger, B. M. Sandmaier, D. G. Maloney, W. I. Bensinger, T. Gooley, and R. Storb
Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings
Blood,
December 15, 2001;
98(13):
3584 - 3588.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Luznik, S. Jalla, L. W. Engstrom, R. Iannone, and E. J. Fuchs
Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide
Blood,
December 1, 2001;
98(12):
3456 - 3464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Lan, D. Zeng, M. Higuchi, P. Huie, J. P. Higgins, and S. Strober
Predominance of NK1.1+TCR{alpha}{beta}+ or DX5+TCR{alpha}{beta}+ T Cells in Mice Conditioned with Fractionated Lymphoid Irradiation Protects Against Graft-Versus-Host Disease: "Natural Suppressor" Cells
J. Immunol.,
August 15, 2001;
167(4):
2087 - 2096.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Michallet, K. Bilger, F. Garban, M. Attal, A. Huyn, D. Blaise, N. Milpied, P. Moreau, P. Bordigoni, M. Kuentz, et al.
Allogeneic Hematopoietic Stem-Cell Transplantation After Nonmyeloablative Preparative Regimens: Impact of Pretransplantation and Posttransplantation Factors on Outcome
J. Clin. Oncol.,
July 15, 2001;
19(14):
3340 - 3349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-F. Yang, C. J. Wu, S. McLaughlin, A. Chillemi, K. S. Wang, C. Canning, E. P. Alyea, P. Kantoff, R. J. Soiffer, G. Dranoff, et al.
CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia
PNAS,
June 19, 2001;
98(13):
7492 - 7497.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K Khawaja, A R Gennery, T J Flood, M Abinun, and A J Cant
Bone marrow transplantation for CD40 ligand deficiency: a single centre experience
Arch. Dis. Child.,
June 1, 2001;
84(6):
508 - 511.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. A. McSweeney, D. Niederwieser, J. A. Shizuru, B. M. Sandmaier, A. J. Molina, D. G. Maloney, T. R. Chauncey, T. A. Gooley, U. Hegenbart, R. A. Nash, et al.
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
Blood,
June 1, 2001;
97(11):
3390 - 3400.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Lan, D. Zeng, P. Huie, J. P. Higgins, and S. Strober
Allogeneic bone marrow cells that facilitate complete chimerism and eliminate tumor cells express both CD8 and T-cell antigen receptor-{alpha}{beta}
Blood,
June 1, 2001;
97(11):
3458 - 3465.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Badros, B. Barlogie, C. Morris, R. Desikan, S. R. Martin, N. Munshi, M. Zangari, J. Mehta, A. Toor, M. Cottler-Fox, et al.
High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions
Blood,
May 1, 2001;
97(9):
2574 - 2579.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Witherspoon, H. J. Deeg, B. Storer, C. Anasetti, R. Storb, and F. R. Appelbaum
Hematopoietic Stem-Cell Transplantation for Treatment-Related Leukemia or Myelodysplasia
J. Clin. Oncol.,
April 15, 2001;
19(8):
2134 - 2141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. R. Drobyski, H. C. Morse III, W. H. Burns, J. T. Casper, and G. Sandford
Protection from lethal murine graft-versus-host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene
Blood,
April 15, 2001;
97(8):
2506 - 2513.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Giralt, P. F. Thall, I. Khouri, X. Wang, I. Braunschweig, C. Ippolitti, D. Claxton, M. Donato, J. Bruton, A. Cohen, et al.
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
Blood,
February 1, 2001;
97(3):
631 - 637.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. R. Appelbaum, J. M. Rowe, J. Radich, and J. E. Dick
Acute Myeloid Leukemia
Hematology,
January 1, 2001;
2001(1):
62 - 86.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
Abstract
Introduction
Abstract